Pharmaceutical Executive Daily: Ultragenyx's Apazunersen Fails Phase III Trial

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today's Pharmaceutical Executive Daily, Ultragenyx shares plunge nearly 45% after its Angelman syndrome drug apazunersen misses its primary and secondary endpoints in a Phase III trial, Mark Cziraky of Carelon Research explains how trusted research environments change data access but not the underlying mechanics of analyzing linked data sets, and Melanie Whittington joins The Ron Lanton Report to argue that biopharma innovation and pricing only make sense when traced back to what they deliver for patients.

Ultragenyx shares drop nearly 45% in after-hours trading after its Phase III trial of apazunersen fails to meet its primary and secondary endpoints in Angelman syndrome, a rare neurodevelopmental disorder affecting roughly 1 in 15,000 births. The drug shows no meaningful difference from placebo on either a test of cognitive and nonverbal reasoning or an overall measure of response, marking the company's second consecutive late-stage trial failure. Ultragenyx says it is reviewing the program's future and plans significant expense reductions, and analysts increasingly frame the company as a commercial and expense story rather than a pipeline execution story.

Pharmaceutical Executive speaks with Mark Cziraky, president of Carelon Research, on the mechanics of analyzing linked, real-world data sets. Cziraky argues that trusted research environments don't change the underlying analytical process, protocol development, preliminary queries, and evidence packaging still follow standard scientific rigor, but they expand the volume and richness of data researchers can access before analysis even begins. He points to FDA's growing acceptance of real-world evidence alongside a single well-controlled trial as a sign of where the field is heading, and notes Carelon's new partnership with Manifold to let researchers analyze their own data alongside third-party data sets in controlled environments.

Finally, Melanie Whittington tells The Ron Lanton Report that biopharmaceutical policy only makes sense when it's traced back to what it delivers for individual patients rather than abstract populations. Whittington argues for a "prize, not price" framework that rewards innovation itself, describing a two-phase social contract in which market-based pricing during patent exclusivity gives way to generic and biosimilar competition that pushes prices toward production costs, pointing to Sovaldi's drop from nearly $80,000 to roughly $10,000 to $15,000 as evidence the model works for small molecules. She cautions that biosimilars and cell and gene therapies pose a tougher test, since biosimilars haven't matched the rapid price declines seen with small-molecule generics.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.